FDA Approves VIGADRONE — Upsher-Smith Laboratories, LLC

Upsher-Smith Laboratories secured FDA approval for its generic Vigabatrin (VIGADRONE) oral formulation on June 21, 2018, via ANDA 210196 to capitalize on a growing market of cost-conscious patients. This approval is set to broaden the company's revenue base and exert competitive pressure on brand-name pricing within the antiepileptic sector.